Abstract:In this review, different integrations of the highly pro‐inflammatory cytokine interleukin‐12 (IL‐12) with existing treatments for solid tumors are highlighted. Promising directions in adoptive cell therapy, viral vectors, and protein engineering are identified and major challenges including a lack of translation of preclinical results to human trials, severe off‐target immunotoxicity, and the selection of complementary treatment are addressed. Finally, the proportions of different immune cell types in solid tumors are analyzed to identify tumors for which IL‐12 has the greatest potential. Immunotherapy describes a class of therapies in which the immune system is manipulated for therapeutic benefit. These treatments include immune checkpoint inhibitors, adoptive cell therapy, and vaccines. For many hematological malignancies, immunotherapy has emerged as an essential treatment component. However, this success has yet to be replicated for solid tumors, which develop advanced physical and molecular mechanisms for suppressing and evading immune destruction. Nevertheless, cytokine immunotherapy presents a potential remedy to these barriers by delivering a proinflammatory immune signal to the tumor and thereby transforming it from immunologically "cold" to "hot." Interleukin‐12 (IL‐12), one of the most potent proinflammatory cytokines, was initially investigated for this purpose. However, initial murine and human studies in which IL‐12 was administered systemically resulted in dangerous immunotoxicity associated with off‐target immune activation. As a result, recent studies have employed advanced cell and molecular engineering approaches to reduce IL‐12 toxicity while increasing or maintaining its efficacy such that its effective doses can be tolerated in humans. This review highlights such developments and identifies promising future directions.

Augmentation of Solid Tumor Immunotherapy With IL‐12